In line with our observations, Ruxolitinib, an FDA-approved inhibitor of upstream STAT3 activating JAK1/2 kinases, enhanced sensitivity of myeloproliferative neoplasms to PARPi treatment (51). This evidence concerns the gene JAK1 and myeloproliferative neoplasm.